ArticleBMJ open2025

Value of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial).

Jiahao Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.